Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Miripirium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.59 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.59 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.59 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.59 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.59 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10385791 | 1.00 | HTT (0.96) | HTTKMT2AMEN1MAPTTP53 | |
| Hydrochloric Acid SCHEMBL330599 | 1.00 | HTT (0.96) | HTTKMT2AMEN1MAPTTP53 | |
| Hydrochloric Acid SCHEMBL30212612 | 1.00 | HTT (0.96) | HTTKMT2AMEN1MAPTTP53 | |
| Hydrochloric Acid SCHEMBL1502731 | 1.00 | HTT (0.96) | HTTKMT2AMEN1MAPTTP53 | |
| Hydrochloric Acid SCHEMBL330017 | 1.00 | HTT (0.96) | HTTKMT2AMEN1MAPTTP53 | |
| Hydrochloric Acid SCHEMBL29252089 | 1.00 | HTT (0.96) | HTTKMT2AMEN1MAPTTP53 | |
| Hydrochloric Acid SCHEMBL1502821 | 1.00 | HTT (0.96) | HTTKMT2AMEN1MAPTTP53 | |
| Hydrochloric Acid SCHEMBL9736042 | 1.00 | HTT (0.96) | HTTKMT2AMEN1MAPTTP53 | |
| Water SCHEMBL15361380 | 0.98 | HTT (0.92) | HTTKMT2AMEN1MAPTTP53 | |
| SCHEMBL5305098 | 0.98 | HTT (1.00) | HTTKMT2AMEN1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 938 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087715-A1 | STIMULUS-RESPONSIVE GELABLE LIQUID COMPOSITION COMPRISING VESICLES | NANOMOL TECHNOLOGIES, S.L. (ES) | 2026-04-30 | — | — | WO | claimed |
| US-20250345306-A1 | ORAL LIQUID FORMULATION OF METHOCARBAMOL | LIQMEDS WORLDWIDE LIMITED (GB) | 2025-11-13 | — | — | US | claimed |
| US-12390439-B2 | Oral liquid formulation of methocarbamol | LIQMEDS WORLDWIDE LIMITED (GB) | 2025-08-19 | — | — | US | claimed |
| US-20250134846-A1 | ORAL LIQUID FORMULATION OF METHOCARBAMOL | LIQMEDS WORLDWIDE LIMITED (GB) | 2025-05-01 | — | — | US | claimed |
| US-20240226002-A9 | SOFT CHEWABLE FORMULATIONS WITH ACTIVE INGREDIENTS | VETS PLUS, INC. | 2024-07-11 | — | — | US | claimed |
| US-20240130964-A1 | SOFT CHEWABLE FORMULATIONS WITH ACTIVE INGREDIENTS | NOBLE PHARMA LLC (US) | 2024-04-25 | — | — | US | claimed |
| US-20230390307-A1 | PEG-FREE AQUEOUS SUSPENSIONS FOR PARENTERAL ADMINISTRATION OF A CORTICOSTEROID | PFIZER INC. (US) | 2023-12-07 | — | — | US | claimed |
| CN-116367840-A | PEG-free aqueous suspensions for parenteral administration of corticosteroids | 辉瑞公司 | 2023-06-30 | — | — | CN | claimed |
| WO-2022079739-A1 | FIXED DOSE COMPOSITIONS OF CABOTEGRAVIR AND RILPIVIRINE | CIPLA LIMITED (IN) | 2022-04-21 | — | — | WO | claimed |
| EP-3263145-B1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR LOCKING CATHETERS | BECTON DICKINSON CO (US) | 2021-01-20 | — | — | EP | claimed |
| US-6787568-B1 | Antibiotic/analgesic formulation and a method of making this formulation | PHOENIX SCIENTIFIC, INC. | 2004-09-07 | — | — | US | claimed |
| US-20040156816-A1 | Lipid-drug complexes in reversed liquid and liquid crystalline phases | LYOTROPIC THERAPEUTICS, INC. | 2004-08-12 | — | — | US | claimed |
| US-20040151759-A1 | Non-animal product containing veterinary formulations | MERIAL LIMITED | 2004-08-05 | — | — | US | claimed |
| US-20040037869-A1 | Non-animal product containing veterinary formulations | MERIAL LIMITED, AND DOMESTICATED IN DELAWARE, USA AS MERIAL LLC (GB) | 2004-02-26 | — | — | US | claimed |
| EP-1345611-A1 | AN ANTIBIOTIC/ANALGESIC FORMULATION AND A METHOD OF MAKING THIS FORMULATION | Phoenix Scientific, Inc. (US) | 2003-09-24 | — | — | EP | claimed |
| US-20030068339-A1 | Florfenicol and a preservative are dissolved in N-methyl-2-pyrrolidone;antibiotics | PHOENIX SCIENTIFIC, INC. | 2003-04-10 | — | — | US | claimed |
| WO-2002041899-A1 | AN ANTIBIOTIC/ANALGESIC FORMULATION AND A METHOD OF MAKING THIS FORMULATION | PHOENIX SCIENTIFIC, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| EP-0311344-B1 | Disposable absorbent articles for incontinent individuals | PROCTER & GAMBLE (US) | 1995-01-04 | — | — | EP | claimed |
| US-4842593-A | DIAPER CONTAINING ACIDIC BUFFER AND MICROBIOCIDE | THE PROCTER & GAMBLE COMPANY (US) | 1989-06-27 | — | — | US | claimed |
| EP-0311344-A2 | Disposable absorbent articles for incontinent individuals | THE PROCTER & GAMBLE COMPANY (US) | 1989-04-12 | — | — | EP | claimed |